{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:04:47Z","timestamp":1793387087269,"version":"4.5.0"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Epidemiology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.annepidem.2025.06.014","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T03:10:51Z","timestamp":1751425851000},"page":"31-37","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Value of public health interventions for HIV, HBV and HCV integrated screening: The FOCUS-CRIVALVIR programme"],"prefix":"10.1016","volume":"109","author":[{"given":"E.","family":"Ortega Gonz\u00e1lez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Dom\u00ednguez-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Mart\u00ednez Roma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MD.","family":"Ocete-Mochon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Carrodeguas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JL.","family":"Gonz\u00e1lez-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MA.","family":"Casado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Garc\u00eda Deltoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.annepidem.2025.06.014_bib1","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.annepidem.2025.06.014_bib2","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/hep.31060","article-title":"AASLD-IDSA Hepatitis C Guidance Panel. Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection","volume":"71","author":"Ghany","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.annepidem.2025.06.014_bib3","unstructured":"Ministerio de Sanidad. Unidad de vigilancia de VIH, ITS y hepatitis. Vigilancia Epidemiol\u00f3gica del VIH y sida en Espa\u00f1a 2020: Sistema de Informaci\u00f3n sobre Nuevos Diagn\u00f3sticos de VIH y Registro Nacional de Casos de Sida. Plan Nacional sobre el Sida \u2013 Divisi\u00f3n de control de VIH, ITS, Hepatitis virales y tuberculosis-DG de Salud P\u00fablica \/ Centro Nacional de Epidemiolog\u00eda - ISCIII. Madrid; Nov 2021. [Internet]. 2021 [cited 2024 Jun 28]. Available from: \u3008https:\/\/www.sanidad.gob.es\/ciudadanos\/enfLesiones\/enfTransmisibles\/sida\/vigilancia\/docs\/Informe_VIH_SIDA_WEB.pdf\u3009."},{"key":"10.1016\/j.annepidem.2025.06.014_bib4","unstructured":"UNAIDS. Hoja informativa \u2014 \u00daltimas estad\u00edsticas sobre el estado de la epidemia de sida [Internet]. [cited 2024 Jun 28]. Available from: https:\/\/www.unaids.org\/es\/resources\/fact-sheet."},{"key":"10.1016\/j.annepidem.2025.06.014_bib5","unstructured":"WHO. Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022-2030. ISBN: 978-92-4-005377-9 [Internet]. [cited 2024 Jun 28]. Available from: \u3008https:\/\/iris.who.int\/bitstream\/handle\/10665\/360348\/9789240053779-eng.pdf?sequence=1\u3009."},{"key":"10.1016\/j.annepidem.2025.06.014_bib6","unstructured":"Ministerio de Sanida. 2o Estudio de seroprevalencia en Espa\u00f1a. Ministerio de Sanidad. Septiembre 2020. [Internet]. 2020 [cited 2024 Jun 28]. Available from: \u3008https:\/\/www.sanidad.gob.es\/biblioPublic\/publicaciones\/recursos_propios\/resp\/revista_cdrom\/VOL95\/C_ESPECIALES\/RS95C_202103059es.pdf\u3009."},{"issue":"5","key":"10.1016\/j.annepidem.2025.06.014_bib7","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.eimc.2014.07.012","article-title":"Hepatitis C virus infection and its relationship to certain sexual practices in men-who-have-sex-with-men in Spain: results from the European MSM internet survey (EMIS)","volume":"33","author":"Fern\u00e1ndez-D\u00e1vila","year":"2015","journal-title":"Enferm Infecc Microbiol Clin"},{"issue":"41","key":"10.1016\/j.annepidem.2025.06.014_bib8","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000030400","article-title":"HIV screening and linkage to care in a health department in Valencia, Spain: Lessons learned from a healthcare quality improvement project","volume":"101","author":"Ortega-Gonzalez","year":"2022","journal-title":"Med (Baltim)"},{"issue":"1","key":"10.1016\/j.annepidem.2025.06.014_bib9","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-01885-0","article-title":"Late presentation of chronic HBV and HCV patients seeking first time specialist care in Spain: a 2-year registry review","volume":"11","author":"Picchio","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.annepidem.2025.06.014_bib10","unstructured":"ISCIII. Unidad de vigilancia del VIH, ITS y hepatitis B y C. Actualizaci\u00f3n del Continuo de Atenci\u00f3n del VIH en Espa\u00f1a, 2021. Madrid: Centro Nacional de Epidemiolog\u00eda \u2013 Instituto de Salud Carlos III\/ Divisi\u00f3n de control de VIH, ITS, Hepatitis Virales y Tuberculosis \u2013 Direcci\u00f3n General de Salud P\u00fablica; 2023 [Internet]. 2023 [cited 2024 Jun 28]. Available from: \u3008https:\/\/www.isciii.es\/QueHacemos\/Servicios\/VigilanciaSaludPublicaRENAVE\/EnfermedadesTransmisibles\/Documents\/VIH\/INFORMES%20ESPECIALES\/ESTIMACION%20DEL%20CONTINUO%20DE%20ATENCI%C3%93N%20DEL%20VIH%20EN%20ESPA%C3%91A_Mayo%202023.pdf\u3009."},{"issue":"10","key":"10.1016\/j.annepidem.2025.06.014_bib11","first-page":"1180","article-title":"The economic burden of HIV-associated wasting in the era of modern antiretroviral therapy","volume":"28","author":"Siddiqui","year":"2022","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"10.1016\/j.annepidem.2025.06.014_bib12","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0213-005X(18)30242-8","article-title":"Healthcare and economic impact","volume":"36","author":"\u00c1lvarez Cabo","year":"2018","journal-title":"Enferm Infecc Microbiol Clin (Engl Ed)"},{"issue":"11","key":"10.1016\/j.annepidem.2025.06.014_bib13","doi-asserted-by":"crossref","first-page":"502","DOI":"10.3390\/tropicalmed8110502","article-title":"Hepatitis C Virus Infection in the Elderly in the Era of Direct-Acting Antivirals: Evidence from Clinical Trials and Real Life","volume":"8","author":"Pugliese","year":"2023","journal-title":"Trop Med Infect Dis"},{"issue":"12","key":"10.1016\/j.annepidem.2025.06.014_bib14","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1097\/MLR.0b013e3181f81c4a","article-title":"HIV Research Network. The economic burden of late entry into medical care for patients with HIV infection","volume":"48","author":"Fleishman","year":"2010","journal-title":"Med Care"},{"issue":"9","key":"10.1016\/j.annepidem.2025.06.014_bib15","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1111\/liv.14126","article-title":"Efficacy and safety of direct-acting antivirals for hepatitis C in the elderly: A systematic review and meta-analysis","volume":"39","author":"M\u00fccke","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.annepidem.2025.06.014_bib16","unstructured":"GeSIDA. Documento de consenso de GeSIDA\/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana [Internet]. 2023 [cited 2024 Jun 28]. Available from: \u3008https:\/\/gesida-seimc.org\/wp-content\/uploads\/2023\/02\/Guia_Modificada_DocumentoDeConsensoDeGeSIDAPlanNacionalSobreElSidaRespectoAlTratamientoAntirretroviralEnAdultosInfectadosPorElVirusDeLaInmunodeficienciaHumana.pdf\u3009."},{"issue":"12","key":"10.1016\/j.annepidem.2025.06.014_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0278544","article-title":"Clinical and economic value of sofosbuvir-based regimens in the treatment of chronic hepatitis C in Spain","volume":"17","author":"Esteban","year":"2022","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.annepidem.2025.06.014_bib18","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.gastrohep.2020.03.011","article-title":"Consensus document of the Spanish Association for Study of the Liver on the treatment of hepatitis B virus infection (2020)","volume":"43","author":"Rodr\u00edguez","year":"2020","journal-title":"Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.annepidem.2025.06.014_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0206755","article-title":"Economic and epidemiologic impact of guidelines for early ART initiation irrespective of CD4 count in Spain","volume":"13","author":"Kasaie","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.annepidem.2025.06.014_bib20","unstructured":"Naciones Unidas. 90-90-90, an ambitious treatment target to help end the AIDS epidemic. 2014. Joint United Nations Program on HIV\/AIDS [Internet]. 2014 [cited 2024 Jun 28]. Available from: \u3008https:\/\/files.unaids.org\/en\/media\/unaids\/contentassets\/documents\/unaidspublication\/2014\/90-90-90_en.pdf\u3009."},{"key":"10.1016\/j.annepidem.2025.06.014_bib21","unstructured":"WHO. Combating hepatitis B and C to reach elimination by 2030: advocacy brief. Geneva. 2016. [Internet]. 2016 [cited 2024 Jun 28]. Available from: \u3008https:\/\/iris.who.int\/bitstream\/handle\/10665\/206453\/WHO_HIV_2016.04_eng.pdf?sequence=\u3009."},{"key":"10.1016\/j.annepidem.2025.06.014_bib22","unstructured":"Ministerio de Sanidad. Plan estrat\u00e9gico para la Prevenci\u00f3n y Control de la Infecci\u00f3n por el VIH y las ITS en Espa\u00f1a. 2021-2030 [Internet]. 2023 [cited 2024 Jun 28]. Available from: \u3008https:\/\/www.sanidad.gob.es\/ciudadanos\/enfLesiones\/enfTransmisibles\/sida\/planNalSida\/Plan_de_Prevencion_y_Control1.pdf\u3009."},{"issue":"2","key":"10.1016\/j.annepidem.2025.06.014_bib23","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.gastrohep.2022.09.009","article-title":"Recommendations for the integral diagnosis of chronic viral hepatitis in a single analytical extraction","volume":"46","author":"Crespo","year":"2023","journal-title":"Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.annepidem.2025.06.014_bib24","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofad666","article-title":"Combined \u201cTest and Treat\u201d Campaigns for Human Immunodeficiency Virus, Hepatitis B, and Hepatitis C: A Systematic Review to Provide Evidence to Support World Health Organization Treatment Guidelines","volume":"11","author":"Beard","year":"2024","journal-title":"Open Forum Infect Dis"},{"issue":"10","key":"10.1016\/j.annepidem.2025.06.014_bib25","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.eimc.2022.07.012","article-title":"Achieving the UNAIDS goals by 2030 in people living with HIV: A simulation model to support the prioritization of health care interventions","volume":"41","author":"Coll","year":"2023","journal-title":"Enferm Infecc Microbiol Clin (Engl Ed)"},{"key":"10.1016\/j.annepidem.2025.06.014_bib26","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.puhe.2024.01.012","article-title":"Universal screening and treatment towards the elimination of chronic hepatitis C in China: an economic evaluation","volume":"228","author":"Fang","year":"2024","journal-title":"Public Health"},{"key":"10.1016\/j.annepidem.2025.06.014_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2024.107131","article-title":"Opportunistic population screening as a hepatitis elimination strategy: The CRIVALVIR-FOCUS program","author":"Ortega Gonz\u00e1lez","year":"2024","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.annepidem.2025.06.014_bib28","unstructured":"Conselleria de Sanitat Universal i Salut P\u00fablica. Memoria de Gesti\u00f3n 2020. Memoria 2020 - Portal estad\u00edstico - portemasdx [Internet]. Portal estad\u00edstico. [cited 2024 Jun 28]. Available from: \u3008https:\/\/www.san.gva.es\/es\/web\/portal-estadistico\/memoria-2020\u3009."},{"key":"10.1016\/j.annepidem.2025.06.014_bib29","unstructured":"Conselleria de Sanidad. Indicador de tratamiento 2018. Sistema de informaci\u00f3n en adicciones. Drogodependencias. Conselleria de Sanidad. Generalitat Valenciana. [Internet]. 2018 [cited 2024 Jun 28]. Available from: \u3008https:\/\/www.san.gva.es\/documents\/d\/drogodependencies\/indicador-tratamiento-2018-_web_cas\u3009."},{"key":"10.1016\/j.annepidem.2025.06.014_bib30","unstructured":"Ministerio de Interior. Estad\u00edstica de la Poblaci\u00f3n Reclusa | CGPJ | Temas | Estad\u00edstica Judicial | Estad\u00edstica por temas | Datos penales, civiles y laborales | Cumplimiento de penas [Internet]. [cited 2024 Jun 28]. Available from: \u3008https:\/\/www.poderjudicial.es\/cgpj\/es\/Temas\/Estadistica-Judicial\/Estadistica-por-temas\/Datos-penales--civiles-y-laborales\/Cumplimiento-de-penas\/Estadistica-de-la-Poblacion-Reclusa\/\u3009."},{"key":"10.1016\/j.annepidem.2025.06.014_bib31","unstructured":"Ipsos. Encuesta LGBT 2021 Ipsos [Internet]. 2021 [cited 2024 Jun 28]. Available from: \u3008https:\/\/www.ipsos.com\/sites\/default\/files\/ct\/news\/documents\/2021-06\/LGBT%20Pride%202021%20Global%20Survey%20Report_3.pdf\u3009."},{"key":"10.1016\/j.annepidem.2025.06.014_bib32","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ijregi.2023.07.001","article-title":"Hepatitis C antibody prevalence and active hepatitis C infection in HIV-negative gay, bisexual, and other men who have sex with men in Barcelona and Madrid, Spain (March 2018-March 2021)","volume":"8","author":"Palma","year":"2023","journal-title":"IJID Reg"},{"issue":"30","key":"10.1016\/j.annepidem.2025.06.014_bib33","doi-asserted-by":"crossref","first-page":"2200738","DOI":"10.2807\/1560-7917.ES.2023.28.30.2200738","article-title":"Estimates of hepatitis B virus prevalence among general population and key risk groups in EU\/EEA\/UK countries: a systematic review","volume":"28","author":"Bivegete","year":"2023","journal-title":"Eur Surveill"},{"key":"10.1016\/j.annepidem.2025.06.014_bib34","unstructured":"Generalitat Valenciana. Proyecciones de poblaci\u00f3n, 2022-2037 - Portal Estad\u00edstico de la Generalitat Valenciana - Generalitat Valenciana [Internet]. Portal Estad\u00edstico de la Generalitat Valenciana. [cited 2024 Jun 28]. Available from: \u3008https:\/\/pegv.gva.es\/va\/inicio\/-\/asset_publisher\/CWK0IEKbs79H\/content\/proyecciones-de-poblaci%25C3%25B3n-2022-2037?_com_liferay_asset_publisher_web_portlet_AssetPublisherPortlet_INSTANCE_CWK0IEKbs79H_assetEntryId=373537558\u3009."},{"key":"10.1016\/j.annepidem.2025.06.014_bib35","unstructured":"Ministerio de Sanidad. Evoluci\u00f3n coberturas de primovacunaci\u00f3n. Espa\u00f1a 2010-2020 [Internet]. 2020 [cited 2024 Jun 28]. Available from: \u3008https:\/\/vacunasaep.org\/sites\/vacunasaep.org\/files\/minsanidad_coberturas-vacunales-2020-tabla01.pdf\u3009."},{"key":"10.1016\/j.annepidem.2025.06.014_bib36","unstructured":"Vacunolog\u00eda AE de. Efectividad de la vacuna [Internet]. Vacunas | Asociaci\u00f3n Espa\u00f1ola de Vacunolog\u00eda. 2018 [cited 2024 Jun 28]. Available from: \u3008https:\/\/vacunas.org\/efectividad-de-la-vacuna-hepatitis-b\/\u3009."},{"issue":"2","key":"10.1016\/j.annepidem.2025.06.014_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0246129","article-title":"Implementation of pre-exposure prophylaxis programme in Spain. Feasibility of four different delivery models","volume":"16","author":"Iniesta","year":"2021","journal-title":"PLoS One"},{"issue":"23","key":"10.1016\/j.annepidem.2025.06.014_bib38","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1056\/NEJMoa1506273","article-title":"On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection","volume":"373","author":"Molina","year":"2015","journal-title":"N Engl J Med"},{"issue":"10013","key":"10.1016\/j.annepidem.2025.06.014_bib39","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(15)00056-2","article-title":"Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial","volume":"387","author":"McCormack","year":"2016","journal-title":"Lancet"},{"key":"#cr-split#-10.1016\/j.annepidem.2025.06.014_bib40.1","unstructured":"Ministerio de Sanidad. Unidad de vigilancia de VIH, ITS y hepatitis B y C. Mortalidad por VIH y sida en Espa\u00f1a, a\u00f1o 2021. Evoluci\u00f3n 1981-2021. Centro Nacional de Epidemiolog\u00eda, Instituto de Salud Carlos III\/Divisi\u00f3n de control de VIH, ITS, Hepatitis Virales y Tuberculosis, Direcci\u00f3n General de Salud P\u00fablica. Madrid"},{"key":"#cr-split#-10.1016\/j.annepidem.2025.06.014_bib40.2","unstructured":"2023. [Internet]. 2021 [cited 2024 Jun 28]. Available from: \u3008https:\/\/www.sanidad.gob.es\/ciudadanos\/enfLesiones\/enfTransmisibles\/sida\/vigilancia\/docs\/Mortalidad_por_VIH2021.pdf\u3009."},{"issue":"5","key":"10.1016\/j.annepidem.2025.06.014_bib41","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.jhep.2021.05.028","article-title":"Impact of direct-acting antivirals for HCV on mortality in a large population-based cohort study","volume":"75","author":"Janjua","year":"2021","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.annepidem.2025.06.014_bib42","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/apt.15803","article-title":"Mortality in adults with chronic hepatitis B infection in the United States: a population-based study","volume":"52","author":"Zhou","year":"2020","journal-title":"Aliment Pharm Ther"},{"key":"10.1016\/j.annepidem.2025.06.014_bib43","unstructured":"INE. INEbase \/ Sociedad \/Salud \/Estad\u00edstica de defunciones seg\u00fan la causa de muerte \/ \u00daltimos datos [Internet]. INE. [cited 2024 Jun 28]. Available from: \u3008https:\/\/www.ine.es\/dyngs\/INEbase\/es\/operacion.htm?c=Estadistica_C&cid=1254736176780&menu=ultiDatos&idp=1254735573175\u3009."},{"key":"10.1016\/j.annepidem.2025.06.014_bib44","unstructured":"BOE. BOE-A-2018-1870 Ley 20\/2017, de 28 de diciembre, de tasas. [Internet]. [cited 2024 Jun 28]. Available from: \u3008https:\/\/www.boe.es\/diario_boe\/txt.php?id=BOE-A-2018-1870\u3009."},{"issue":"12","key":"10.1016\/j.annepidem.2025.06.014_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0260608","article-title":"Clinical and economic impact of an alert system in primary care for the detection of patients with chronic hepatitis C","volume":"16","author":"Garc\u00eda-Herola","year":"2021","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.annepidem.2025.06.014_bib46","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1080\/09540121.2017.1417528","article-title":"Can we afford to offer pre-exposure prophylaxis to MSM in Catalonia? Cost-effectiveness analysis and budget impact assessment","volume":"30","author":"Reyes-Urue\u00f1a","year":"2018","journal-title":"AIDS Care"},{"issue":"7","key":"10.1016\/j.annepidem.2025.06.014_bib47","first-page":"433","article-title":"Cost-effectiveness analysis of two treatment strategies for chronic hepatitis C before and after access to direct-acting antivirals in Spain. Gastroenterol Hepatol","volume":"40","author":"Turnes","year":"2017"},{"key":"10.1016\/j.annepidem.2025.06.014_bib48","unstructured":"\u00b4Ram\u00edrez M. El precio del diagnostico tard\u00edo (DT). SIDA STUDI [Internet]. SIDA STUDI. [cited 2024 Jun 28]. Available from: \u3008http:\/\/www.sidastudi.org\/es\/registro\/a53b7fb36f185104016f380635560027\u3009."},{"issue":"2","key":"10.1016\/j.annepidem.2025.06.014_bib49","first-page":"221","article-title":"The Efficiency of Increased HCV Testing and Treatment Strategies in Spain to Achieve Elimination Goals","volume":"8","author":"Calleja","year":"2024","journal-title":"Pharm Open"},{"issue":"10","key":"10.1016\/j.annepidem.2025.06.014_bib50","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.eimc.2021.05.006","article-title":"Clinical and economic benefit of 32 years of antiretroviral treatment for people living with HIV in Spain: Has it been an efficient intervention?","volume":"40","author":"P\u00e9rez-El\u00edas","year":"2022","journal-title":"Enferm Infecc Microbiol Clin (Engl Ed)"},{"issue":"3","key":"10.1016\/j.annepidem.2025.06.014_bib51","first-page":"415","article-title":"Epidemiologic and Economic Analysis of Rapid Antiretroviral Therapy Initiation with Bictegravir\/Emtricitabine\/Tenofovir Alafenamide in Spain","volume":"6","author":"Estrada","year":"2022","journal-title":"Pharm Open"},{"issue":"2","key":"10.1016\/j.annepidem.2025.06.014_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087872","article-title":"Expansion of HAART coverage is associated with sustained decreases in HIV\/AIDS morbidity, mortality and HIV transmission: the \u201cHIV Treatment as Prevention\u201d experience in a Canadian setting","volume":"9","author":"Montaner","year":"2014","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.annepidem.2025.06.014_bib53","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011068","article-title":"Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco","volume":"5","author":"Das","year":"2010","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.annepidem.2025.06.014_bib54","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/jvh.12881","article-title":"Direct medical costs associated with the extrahepatic manifestations of hepatitis C infection in Europe","volume":"25","author":"Cacoub","year":"2018","journal-title":"J Viral Hepat"},{"issue":"8","key":"10.1016\/j.annepidem.2025.06.014_bib55","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s10198-022-01540-z","article-title":"The effect of hepatitis C-associated premature deaths on labour productivity losses in Spain: a ten-year analysis","volume":"24","author":"Pe\u00f1a-Longobardo","year":"2023","journal-title":"Eur J Health Econ"},{"issue":"3","key":"10.1016\/j.annepidem.2025.06.014_bib56","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/jvh.12483","article-title":"Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C (CH-C) patients: an economic model from five European countries","volume":"23","author":"Younossi","year":"2016","journal-title":"J Viral Hepat"},{"issue":"8","key":"10.1016\/j.annepidem.2025.06.014_bib57","doi-asserted-by":"crossref","first-page":"967","DOI":"10.4065\/82.8.967","article-title":"Natural history of hepatitis B virus infection: an update for clinicians","volume":"82","author":"Pungpapong","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"12","key":"10.1016\/j.annepidem.2025.06.014_bib58","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.3390\/microorganisms11122874","article-title":"Updates on Hepatitis B Virus (HBV) Infection 2.0","volume":"11","author":"Chemin","year":"2023","journal-title":"Microorganisms"},{"issue":"1","key":"10.1016\/j.annepidem.2025.06.014_bib59","first-page":"1","article-title":"The transferability of economic evaluations: Concept and instruments of measure [La transferibilidad de las evaluaciones econ\u00f3micas: Concepto e instrumentos de medida","volume":"9","author":"Anto\u00f1anzas","year":"2012","journal-title":"PharmacoEconomics"},{"issue":"1","key":"10.1016\/j.annepidem.2025.06.014_bib60","doi-asserted-by":"crossref","DOI":"10.1017\/S026646232200321X","article-title":"Considerations for transferability of health technology assessments: a scoping review of tools, methods, and practices","volume":"38","author":"Heupink","year":"2022","journal-title":"Int J Technol Assess Health Care"},{"issue":"4","key":"10.1016\/j.annepidem.2025.06.014_bib61","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/QAD.0000000000002103","article-title":"Reinfection by hepatitis C virus following effective all-oral direct-acting antiviral drug therapy in HIV\/hepatitis C virus coinfected individuals","volume":"33","author":"Berenguer","year":"2019","journal-title":"AIDS"}],"container-title":["Annals of Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104727972500136X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104727972500136X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T14:55:48Z","timestamp":1762354548000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104727972500136X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":62,"alternative-id":["S104727972500136X"],"URL":"https:\/\/doi.org\/10.1016\/j.annepidem.2025.06.014","relation":{},"ISSN":["1047-2797"],"issn-type":[{"value":"1047-2797","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Value of public health interventions for HIV, HBV and HCV integrated screening: The FOCUS-CRIVALVIR programme","name":"articletitle","label":"Article Title"},{"value":"Annals of Epidemiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annepidem.2025.06.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}